Canada, Merck Ink Supply Pact For 1M Doses Of Molnupiravir For COVID-19

Merck & Co Inc MRK has entered into a Supply Agreement with the Government of Canada for up to 1 million patient courses of molnupiravir for COVID-19.
In collaboration with Ridgeback Biotherapeutics, Merck is developing the investigational COVID-19 medicine.
Through the agreement, the Government of Canada has secured access in 2022 to 500,000 patient courses, with options for up to 500,000 more, pending Health Canada approval.
In November, Merck Canada filed the final wave of the molnupiravir rolling submission to Health Canada, which will decide on the therapy's approval.
Earlier this year, Merck entered into a procurement agreement with the U.S. Government. Merck will supply approximately 3.1 million courses of molnupiravir upon Emergency Use Authorization or approval from the FDA.
Related Link: AdComm Narrowly Backs Merck's COVID-19 Pill, Despite Efficacy Questions.
Price Action: MRK shares are down 0.16% at $73.22 during the premarket session on the last check Monday.